215 related articles for article (PubMed ID: 24386891)
1. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.
Marcsisin SR; Sousa JC; Reichard GA; Caridha D; Zeng Q; Roncal N; McNulty R; Careagabarja J; Sciotti RJ; Bennett JW; Zottig VE; Deye G; Li Q; Read L; Hickman M; Dhammika Nanayakkara NP; Walker LA; Smith B; Melendez V; Pybus BS
Malar J; 2014 Jan; 13():2. PubMed ID: 24386891
[TBL] [Abstract][Full Text] [Related]
2. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.
Pybus BS; Marcsisin SR; Jin X; Deye G; Sousa JC; Li Q; Caridha D; Zeng Q; Reichard GA; Ockenhouse C; Bennett J; Walker LA; Ohrt C; Melendez V
Malar J; 2013 Jun; 12():212. PubMed ID: 23782898
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Milner EE; Berman J; Caridha D; Dickson SP; Hickman M; Lee PJ; Marcsisin SR; Read LT; Roncal N; Vesely BA; Xie LH; Zhang J; Zhang P; Li Q
Malar J; 2016 Dec; 15(1):588. PubMed ID: 27923405
[TBL] [Abstract][Full Text] [Related]
4. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.
Li Q; O'Neil M; Xie L; Caridha D; Zeng Q; Zhang J; Pybus B; Hickman M; Melendez V
Malar J; 2014 Apr; 13():141. PubMed ID: 24731238
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
[TBL] [Abstract][Full Text] [Related]
7. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.
Potter BM; Xie LH; Vuong C; Zhang J; Zhang P; Duan D; Luong TL; Bandara Herath HM; Dhammika Nanayakkara NP; Tekwani BL; Walker LA; Nolan CK; Sciotti RJ; Zottig VE; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Marcsisin SR
Antimicrob Agents Chemother; 2015 Apr; 59(4):2380-7. PubMed ID: 25645856
[TBL] [Abstract][Full Text] [Related]
8. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.
Pybus BS; Sousa JC; Jin X; Ferguson JA; Christian RE; Barnhart R; Vuong C; Sciotti RJ; Reichard GA; Kozar MP; Walker LA; Ohrt C; Melendez V
Malar J; 2012 Aug; 11():259. PubMed ID: 22856549
[TBL] [Abstract][Full Text] [Related]
9. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
[TBL] [Abstract][Full Text] [Related]
10. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.
Marcsisin SR; Reichard G; Pybus BS
Pharmacol Ther; 2016 May; 161():1-10. PubMed ID: 27016470
[TBL] [Abstract][Full Text] [Related]
11. The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Peters W; Stewart LB; Robinson BL
Ann Trop Med Parasitol; 2003 Apr; 97(3):221-36. PubMed ID: 12803854
[TBL] [Abstract][Full Text] [Related]
12. The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).
Dow G; Smith B
Malar J; 2017 May; 16(1):209. PubMed ID: 28526056
[TBL] [Abstract][Full Text] [Related]
13. Anti-malarial activity of the root extract of Euphorbia abyssinica (Euphorbiaceae) against Plasmodium berghei infection in mice.
Muluye AB; Desta AG; Abate SK; Dano GT
Malar J; 2019 Jul; 18(1):261. PubMed ID: 31362744
[TBL] [Abstract][Full Text] [Related]
14. Endoperoxide-8-aminoquinoline hybrids as dual-stage antimalarial agents with enhanced metabolic stability.
Capela R; Magalhães J; Miranda D; Machado M; Sanches-Vaz M; Albuquerque IS; Sharma M; Gut J; Rosenthal PJ; Frade R; Perry MJ; Moreira R; Prudêncio M; Lopes F
Eur J Med Chem; 2018 Apr; 149():69-78. PubMed ID: 29499488
[TBL] [Abstract][Full Text] [Related]
15. Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure.
Srinivasan S; Roy D; Chavas TEJ; Vlaskin V; Ho DK; Pottenger A; LeGuyader CLM; Maktabi M; Strauch P; Jackson C; Flaherty SM; Lin H; Zhang J; Pybus B; Li Q; Huber HE; Burke PA; Wesche D; Rochford R; Stayton PS
J Control Release; 2021 Mar; 331():213-227. PubMed ID: 33378692
[TBL] [Abstract][Full Text] [Related]
16. Impact of chrysosplenetin on the pharmacokinetics and anti-malarial efficacy of artemisinin against Plasmodium berghei as well as in vitro CYP450 enzymatic activities in rat liver microsome.
Wei S; Ji H; Yang B; Ma L; Bei Z; Li X; Dang H; Yang X; Liu C; Wu X; Chen J
Malar J; 2015 Nov; 14():432. PubMed ID: 26537009
[TBL] [Abstract][Full Text] [Related]
17. Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice.
Melariri P; Kalombo L; Nkuna P; Dube A; Hayeshi R; Ogutu B; Gibhard L; deKock C; Smith P; Wiesner L; Swai H
Int J Nanomedicine; 2015; 10():1493-503. PubMed ID: 25759576
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anti-malarial activity of novel harmine-analog heat shock protein 90 inhibitors: a possible partner for artemisinin.
Bayih AG; Folefoc A; Mohon AN; Eagon S; Anderson M; Pillai DR
Malar J; 2016 Dec; 15(1):579. PubMed ID: 27903279
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
Suarez-Kurtz G
Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
[TBL] [Abstract][Full Text] [Related]
20. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]